Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking.

Susa M, Choy E, Liu X, Schwab J, Hornicek FJ, Mankin H, Duan Z.

Mol Cancer Ther. 2010 Dec;9(12):3342-50. doi: 10.1158/1535-7163.MCT-10-0637. Epub 2010 Sep 29.

2.

Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.

Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, Yang C, Mankin H, Hornicek FJ.

Cancer Lett. 2010 Jul 28;293(2):220-9. doi: 10.1016/j.canlet.2010.01.014. Epub 2010 Feb 9.

PMID:
20144850
3.

The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling.

Zhang L, Gjoerup O, Roberts TM.

Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10296-301. Epub 2004 Jul 6.

4.

ROCK1 as a potential therapeutic target in osteosarcoma.

Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, Duan Z.

J Orthop Res. 2011 Aug;29(8):1259-66. doi: 10.1002/jor.21403. Epub 2011 Mar 8.

5.

The kinase Mirk is a potential therapeutic target in osteosarcoma.

Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, Liu X, Mankin H, Duan Z.

Carcinogenesis. 2010 Apr;31(4):552-8. doi: 10.1093/carcin/bgp330. Epub 2009 Dec 30.

6.

Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.

Sakurai MA, Ozaki Y, Okuzaki D, Naito Y, Sasakura T, Okamoto A, Tabara H, Inoue T, Hagiyama M, Ito A, Yabuta N, Nojima H.

PLoS One. 2014 Jun 27;9(6):e100124. doi: 10.1371/journal.pone.0100124. eCollection 2014.

7.

Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors.

Lee DW, Zhao X, Zhang F, Eisenberg E, Greene LE.

J Cell Sci. 2005 Sep 15;118(Pt 18):4311-21.

8.

Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma.

Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K.

Cancer Sci. 2009 Jul;100(7):1227-33. doi: 10.1111/j.1349-7006.2009.01165.x. Epub 2009 Apr 15.

9.

A kinome-wide siRNA screen identifies multiple roles for protein kinases in hypoxic stress adaptation, including roles for IRAK4 and GAK in protection against apoptosis in VHL-/- renal carcinoma cells, despite activation of the NF-κB pathway.

Pan J, Zhang J, Hill A, Lapan P, Berasi S, Bates B, Miller C, Haney S.

J Biomol Screen. 2013 Aug;18(7):782-96. doi: 10.1177/1087057113484803. Epub 2013 Apr 16.

PMID:
23591012
10.

GAK, a regulator of clathrin-mediated membrane trafficking, localizes not only in the cytoplasm but also in the nucleus.

Sato J, Shimizu H, Kasama T, Yabuta N, Nojima H.

Genes Cells. 2009 May;14(5):627-41. doi: 10.1111/j.1365-2443.2009.01296.x. Epub 2009 Apr 15.

11.

Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.

Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C, Rédini F, Heymann D, Blanchard F.

J Bone Miner Res. 2004 Nov;19(11):1850-61. Epub 2004 Aug 23.

12.

GAK, a regulator of clathrin-mediated membrane traffic, also controls centrosome integrity and chromosome congression.

Shimizu H, Nagamori I, Yabuta N, Nojima H.

J Cell Sci. 2009 Sep 1;122(Pt 17):3145-52. doi: 10.1242/jcs.052795. Epub 2009 Aug 4.

14.

[Knockdown of cyclin A2 expression by small interfering RNA in MG-63 cells].

Liu Y, Ding JY, Shen WL, Zhao X, Fan SW.

Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):670-5. Chinese.

PMID:
18246796
15.

Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.

Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, Milane L, Amiji MM, Duan Z.

PLoS One. 2010 May 24;5(5):e10764. doi: 10.1371/journal.pone.0010764.

16.

AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.

Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S.

J Virol. 2015 Apr;89(8):4387-404. doi: 10.1128/JVI.02705-14. Epub 2015 Feb 4.

17.

Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation.

Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P, Mankin H, Gray NS, Hornicek FJ.

Clin Cancer Res. 2012 Sep 1;18(17):4580-8. doi: 10.1158/1078-0432.CCR-12-1157. Epub 2012 Jul 12.

18.

Functional and biological analysis of Bcl-xL expression in human osteosarcoma.

Wang ZX, Yang JS, Pan X, Wang JR, Li J, Yin YM, De W.

Bone. 2010 Aug;47(2):445-54. doi: 10.1016/j.bone.2010.05.027. Epub 2010 May 23.

PMID:
20580954
19.

Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.

Sévère N, Dieudonné FX, Marty C, Modrowski D, Patiño-García A, Lecanda F, Fromigué O, Marie PJ.

J Bone Miner Res. 2012 Oct;27(10):2108-17. doi: 10.1002/jbmr.1667.

20.

Small interfering RNA-directed knockdown of S100A4 decreases proliferation and invasiveness of osteosarcoma cells.

Ma X, Yang Y, Wang Y, An G, Lv G.

Cancer Lett. 2010 Dec 28;299(2):171-81. doi: 10.1016/j.canlet.2010.08.016. Epub 2010 Sep 19.

PMID:
20855150
Items per page

Supplemental Content

Write to the Help Desk